ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Bringing Precision Medicine to Traumatic Brain Injury Treatment
Reporting on ICON's contribution to a complex pan-European traumatic brain injury (TBI) research study.
Trending 2018: What Does the Future Hold?
Commentary from PV100 honouree Bill Byrom, on prevailing trends in the industry.
Building a Comprehensive Real World Evidence Strategy
How a fully integrated, multidisciplinary RWE model can save time, money and effort in study development and execution.
A Rare Journey: Managing the Regulatory Landscape
ICON contributes to this article in PharmaVOICE looking at efforts undertaken to progress the development of rare disease drugs.
Adaptive Clinical Trial Designs Are Innovative
Article featuring commentary from Rolf Hövelmann and Parvin Fardipour on tackling the operational challenges of adaptive trials.
Big Changes for EU Medical and In Vitro Diagnostic Device Regulations
MDR and IVDR regulations.
CROs and Next-Gen Drug Development
CROs and Next-Gen Drug Development
Is There A Better Way To Value Asset Duration In Biopharma Deal-Making?
ICON’s Andy Smith discusses the role of duration in the valuation of early-stage biopharma assets in this In Vivo article.
Time Is Money
The role of duration in the valuation of early-stage biopharma assets in this In Vivo article.
Proving Real World Value
In the July/Aug issue of PME, Ramita Tandon discusses how to use real world intelligence to demonstrate drug efficacy and cost-effectiveness.